LatchBio Releases Antibody Discovery Benchmark for AI Agents
LatchBio released the Antibody Discovery Benchmark, designed to test whether AI agents can make scientific decisions across stages of therapeutic antibody discovery. It comprises 100 evaluations across 10 domains, all drawn from real drug programs. Early results show Anthropic's Opus and Gemini leading while OpenAI models generally underperform.
Confirmed
- The benchmark was released by LatchBio under the name Antibody Discovery Benchmark
- It contains 100 evaluations across 10 domains
- All evaluations come from real drug programs, covering stages such as target and modality selection, experiment design, and binder discovery
- Results: Opus and Gemini lead; OpenAI models generally score poorly
Why it matters
- The benchmark extends AI evaluation from general capabilities to multi-stage, highly specialized scientific decision-making in drug development
- Notable performance gaps across vendors offer guidance for choosing AI tools in biopharma
2026-09-03 ~ 2026-09-04 · 5 related posts
Primary sources
- [source] Antibody Discovery Benchmark: 100 evals to test AI agents' scientific decisions across drug discovery — kenbwork · 2026-09-03
- LatchBio launches Antibody Discovery Benchmark: 100 evals testing AI agents' scientific decisions — kenbwork · 2026-09-03
- LatchBio's antibody discovery benchmark: Opus and Gemini lead, OpenAI models underperform — kenbwork · 2026-09-03
2 near-duplicate retellings: anshulkundaje · kenbwork